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Abstract Cereblon (CRBN) is essential for the anti-myeloma
(MM) activity of immunomodulatory drugs (IMiDs), such as
thalidomide and lenalidomide. However, the clinical implica-
tions of CRBN in MM patients are unclear. Using immuno-
histochemical (IHC) staining on paraffin-embedded bone
marrow sections, the expression of CRBN protein in myeloma
cells (MCs) was assessed in 40 relapsed/refractory MM
(RRMM) pa t i en t s who rece ived l ena l idomide /
dexamethasone (LD) and 45 and 22 newly diagnosed MM
(NDMM) patients who received thalidomide/dexamethasone
(TD) andmelphalan/bortezomib/prednisolone (MVP), respec-
tively. IHC staining were scored on a scale representing the
diffuseness and intensity of positive-staining MCs (range, 0–
8) and a score ≥4.5 was used for CRBN positivity (CRBN+)
on a cut-point analysis of all possible scores and response of
TD and LD. Compared to CRBN+ NDMM patients, CRBN−
NDMM patients had more international staging system (ISS)
III (26 vs. 61 %, respectively; P=0.006). In the LD and TD
cohorts, the response rate (RR) was higher in CRBN+ patients
than CRBN− patients (LD 79 vs. 33 %, respectively;
P=0.005) (TD 75 vs. 29%, respectively; P=0.005); however,
this trend was not observed in the MVP cohort. In the LD and
TD cohorts, the positive and negative prediction value of
CRBN+ for treatment response was 79 and 67 % and 75 and
71 %, respectively. Multivariate analysis showed that CRBN+
was a significant factor associated with superior RR for LD
and TD. The data suggest that expression of CRBN protein in
MCs assessed using the IHC is a feasible approach to predict
the response of IMiDs in MM patients.
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Introduction
Multiple myeloma (MM) is a malignant plasma cell (PC)
proliferation typically found in bone marrow (BM) [1]. Anti-
MM treatment has advanced in the past decade with the
availability of several novel agents that improve the survival
rates of MM patients [1, 2]. These novel agents include
immunomodulatory drugs (IMiDs), such as thalidomide and
its derivatives, lenalidomide, and pomalidomide. Although
several mechanisms have been proposed to explain the anti-
MM effect of IMiDs [3], the precise molecular mechanisms
remain unclear. Cereblon (CRBN) was recently identified as a
primary target for thalidomide teratogenicity; thalidomide
directly binds to CRBN and subsequently disrupts the func-
tion of CRBN-related E3-ubiquitin ligase complex (E3ULC),
resulting in abnormal regulation of bone morphogenetic pro-
tease and fibroblast growth factors signaling pathways and of
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developmental programs that require their normal functions
[4]. Furthermore, CRBN is required for the anti-MM activity
of the IMiDs [5]. The absence and downregulation of CRBN
expression in human myeloma cell lines result in IMiDs
resistance, which is also supported by downregulation of
CRBN expression at the time of lenalidomide resistance in
MM patients [5].
CRBN was first identified by Higgins et al. [6] in patients
with autosomal recessive nonsyndromic mental retardation.
The human CRBN gene mapped at chromosome 3p26 con-
tains 11 exons and is conserved from plants to humans. CRBN
encodes a 442-amino acid protein with a molecular weight of
approximately 51kD with an ATP-dependent Lon protease
domain and several phosphorylation sites that selectively de-
grade short-lived polypeptides and regulate mitochondrial
replication and transcription [7]. CRBN can interact with the
DNA damage-binding protein-1 (DDB1), Cullin 4 (Cul4A or
Cul4B), and regulator of Cullins 1 (RoC1) to form a function-
al E3ULC [8]. The CRBN-DDB1-Cul4A-RoC1 E3ULC
(CRBN-based E3ULC) attaches polyubiquitin chains to target
proteins for degradation through the ubiquitin–proteasome
protein degradation pathway [7, 8]. Although the substrates
of CRBN, as a putative substrate receptor of the CRBN-based
E3ULC, remain unidentified, the CRBN-based E3ULC has
auto-ubiquitination activity in the absence of their specific
substrates, which is inhibited by thalidomide [4], suggesting
that binding of thalidomide to CRBNmay inhibit the function
of CRBN-based E3ULC [7]. In addition to thalidomide,
lenalidomide and pomalidomide also bind CRBN and inhibit
the auto-ubiquitination of CRBN [9]. Very recently, two spe-
cific B-cell transcription factors, Ikaros family zinc finger-
containing protein 1 (IKZF1; Ikaros) and 3 (IKZF3; Aiolos),
were found to be the targets of lenalidomide-CRBN
ubiquitination degradation in myeloma cells including not
only cell lines but also primary myeloma samples [10, 11].
Binding lenalidomide or its analogues, thalidomide and
pomalidomide, to CRBN would increase the binding of
IKZF1 (Ikaros) and IKZF3 (Aiolos) proteins to the CRBN-
based E3ULC, leading to increased ubiquitination and conse-
quent degradation, which is toxic to myeloma cells [11].
Lenalidomide did not alter IKZF1 and IKZF3 mRNA levels,
consistent with it acting posttranscriptionally [10]. Further-
more, under physiological conditions, IKZF1 and IKZF3 re-
press IL-2 gene expression in T cells but conversely stimulate
expression of interferon-related factor 4 (IRF4) (a transcription
factor essential for survival of myeloma cells) [11, 12]. In
primary human T cells treated with lenalidomide, both IKZF1
and IKZF3 protein levels decreased markedly, suggesting that
induction of IL-2 is mediated by derepression of the IL-2 gene
expression by depletion of IKZF1 and IKZF3 [10, 11]. Thus, a
decrease in IKZF1 and IKZF3 explains the perplexing question
of how IMiDs can both activate the immune system (a boost in
IL-2 production by T cells stimulates immune responses) and
degrade B cell function (as the result of reduced IRF4 expres-
sion) simultaneously [12].
Several clinical studies have correlated the higher expres-
sion of CRBN gene in myeloma cells with the superior treat-
ment response of a lenalidomide-based regimen [13] and a
pomalidomide-based regimen [14], as well as longer
progression-free survival during thalidomide maintenance
therapy [15]. However, the requirement for high-quality clin-
ical samples, such as myeloma cells enrichment by cell
sorting, limits the validation of such quantified transcriptional
expression of the CRBN genemethod to everyMMpatient. In
addition, the lack of a consensus protocol to amplify the
CRBN gene is a crucial problem [16]. In particular, CRBN
frequently undergoes mRNA alternative splicing, and several
isoforms have been described in MM [16, 17]. Some of the
identified mRNA isoforms were even not translated [17]. The
arbitrarily used cutoff level for the transcriptional level of
CRBN gene expression is also difficult to determine consis-
tently [14, 15]. Therefore, the design of the quantitative re-
verse transcription PCR (qRT-PCR) test to assess CRBN
expression levels is critical and can yield variable results
[16]. Low CRBN expression levels were detectable in
CD138 negative cells, representing non-myeloma cells within
a BM microenvironment [13], which may result in a misin-
terpretation of the CRBN gene expression level if the sorting
of CD138 positive myeloma cells is not sufficiently pure.
Therefore, immunohistochemical (IHC) staining may be an
alternative approach for differentiating the myeloma cells and
non-myeloma cells components in BM, and is easier to use for
MM patients, including those with a low percentage of
plasmacytosis in BM. Because the clinical implication of
CRBN translational protein expression, rather than transcrip-
tional gene expression, inMMpatients treated with IMiDs has
not been efficiently examined, we retrospectively analyzed the
expression of CRBN protein in myeloma cells using IHC
staining on paraffin-embedded BM tissues in MM patients
who had received thalidomide or lenalidomide plus dexa-
methasone treatment to correlate the clinical features of MM
patients with CRBN protein expression and evaluate the pos-
sibility of CRBN protein as a biomarker to predict the treat-
ment response of IMiDs.
Methods
Patients and bone marrow samples
Since January 2011, a total of 40 patients with relapsed and/or
refractory MM (RRMM), who had uniformly received
lenalidomide and dexamethasone (LD) as their salvage treat-
ment, were enrolled. BM biopsies of these RRMM patients
were collected around the commencement of LD (median of
−2 days, ranging from −3 to 2 days). Two additional cohorts of
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patients with newly diagnosed MM (NDMM) were enrolled;
one cohort had thalidomide and dexamethasone (TD, N=45)
and the other cohort had melphalan, bortezomib, and prednis-
olone (MVP, N=22) as their induction regimens. The BM
samples of the NDMMpatients at diagnosis were also obtained.
The treatment schedules for LD [18], TD [19], and MVP [20],
as well as the related dosage adjustment [1] were described
previously. This study was approved by our institutional ethics
committee, and written informed consent was obtained from all
patients in accordance with the Declaration of Helsinki.
Treatment response
The treatment response, progression-free survival (PFS), time
to progression (TTP), duration of response (DOR), and overall
survival (OS) were evaluated according to the IMWG con-
sensus criteria [21, 22].
Immunohistochemistry staining
The procedures of immunohistochemistry (IHC) staining in
our laboratory were described as previously [23] with optimi-
zation for this study. Briefly, the BM biopsied samples were
fixed in 10 % neutral buffered formaldehyde for at least 24 h,
decalcified with Shandon TBO-2 decalcifier (Thermo Scien-
tific, US) for 2 h, and embedded in paraffin. Paraffin-
embedded BM tissue sections measuring 4 to 5 μm were
deparaffinized in xylene, rehydrated with ethanol, and rinsed
in PBS. After deparaffinization and rehydration, the slides
were placed in the target retrieval solution (S1700, Dako,
Denmark) and heated (90 °C to 99 °C) for 40 min. Endoge-
nous peroxidase was then blocked with 3 % hydrogen perox-
ide (Dako, Denmark); blocking nonspecific protein binding
with 10 % ovalbumin (EndoGrade®, Hyglos GmbH, Germa-
ny). After blocking, the slides were incubated with the prima-
ry antibody at room temperature for 30 min. The primary
antibodies were monoclonal mouse anti-human CD138
(IgG1, MI15, Dako, Denmark) at a dilution of 1:100, and
polyclonal rabbit anti-human cereblon antibody (IgG,
11435-1-AP, Proteintech, US) at a dilution of 1:50. After
incubation with universal biotinylated link antibody and
peroxidase-conjugated streptavidin, the reaction was achieved
with the DAB substrate-chromogen solution using Universal
Dako LSAB® + Kit (K0679, Dako, Denmark) according to
the instructions of the manufacturer, followed by
counterstaining with hematoxylin (00–8001, Invitrogen Cam-
arillo, CA) for 10 min. Hepatic tissue obtained from the
institutional tissue bank was used as a positive control for
CRBN IHC staining, because of its high expression of CRBN
[24]. Cardiac tissues were used as a negative control because
of its no expression of CRBN [24]. Monoclonal rabbit anti-
human IgG1–4 antibody (EPR4421, Abcam Inc, MA, US) at a
dilution of 1:500 was used as a negative idiotype control. Each
batch of IHC slides was accompanied by the positive and
negative control. The location of myeloma cells were identi-
fied by CD138 positive membrane staining. CRBN immuno-
stained slides were scored as previously described [25] with
modification. In brief, each slide of BM trephine core biopsy
immunostained for CD138 was firstly visualized at ×100
magnification to determine three “hot areas”, namely areas
containing themaximum number of CD138 positivemyeloma
cells. The three “hot areas” were then identified at another
slide immunostained with anti-CRBN antibody by using the
very near slice to the CD138 immunostained slice and were
examined at ×400 magnification. A brown granular or diffuse
cytoplasmic and/or nuclear staining for CRBN within myelo-
ma cells were considered to be positive. Then, a diffuseness
score was assigned, which represented the estimated diffuse-
ness of CRBN positive cells within the hot area (0, none; 1,
<1⁄100; 2, 1⁄100 to <1⁄10; 3, 1⁄10 to <1⁄3; 4, 1⁄3 to 2⁄3; and 5,
>2⁄3). Next, an intensity score was assigned, which represent-
ed the average intensity of CRBN positive cells (0, none; 1,
weak, 2, intermediate; and 3, strong). The diffuseness and
intensity scores were then added to obtain a total score, which
ranged from 0 to 8. The total score in each hot area was
obtained and the average total score for the three hot areas
were calculated and presented. The CRBN IHC staining was
interpreted by two independent and trained reviewers, and the
scores were assigned. The results of equivocal cases were
interpreted and determined by a third independent reviewer.
Statistics
Chi-square or Fisher’s exact tests were used for between-
group comparisons of the discrete variables. A two-sample t
test or one-way ANOVA was used for between-group com-
parison of the means. Pearson’s correlation tests were used to
analyze the continuous variables, and Spearman correlation
was used for the nominal variables. Kaplan–Meier survival
curves were constructed to estimate PFS, TTP, DOR, and OS,
and the differences between groups were compared using the
log-rank test. Inter-reviewer agreement was evaluated using
Cohen’s kappa value [26]. In the analyses, identified salient
variables for clinical and laboratory data were categorized as
described previously [27]. The variables were as follows: age
≥60 years, stage ≥international staging system (ISS) III, light
chain isotype, BM plasmacytosis ≥30 %, beta-2-
microglobulin (β2M) ≥2.5 mg/L, hemoglobin (HB) ≥10g/
dL, white blood cell ≥4.0×109/L, platelet ≥1.5×1011/L, lactate
dehydrogenase (LDH) ≥upper normal limit (UNL), alkaline
phosphatase ≥UNL, calcium (Ca) ≥2.4 μmol/L, creatinine
(Cr) ≥2 mg/dL, and C-reactive protein (CRP) <UNL
(0.8 mg/dL). Factors that provided statistically significant
predictive power in univariate analysis were further tested
using multivariate regression analysis of the linear, logistic,
or Cox type, with forward stepwise selection. All directional P
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values were two-tailed, with a P value of 0.05 or less consid-
ered significant for all tests. All analyses were performed
using SPSS 19.0 software (Chicago, IL, USA).
Results
Patients
The salient clinical characteristics of the 40 RRMMpatients at
commencement of LD are shown in Table 1. The median
therapy prior to LD was 2 lines (range of 1–5 lines). The
median time from diagnosis of MM to LD treatment was
34 months (range of 3–151 months). In total, 93, 75, and
40 % of patients had been exposed to thalidomide,
bortezomib, and high-dose chemotherapy followed by autol-
ogous stem cell transplantation (HDT/AuSCT), respectively.
The salient features of NDMM patients at diagnosis in two
additional cohorts are shown in Table 1.
CRBN immunohistochemical staining and associated clinical
features
The positive and negative controls of CRBN IHC staining on
hepatic and cardiac tissues are shown in Fig 1. The typical
myeloma cells stained positive for CRBN is shown in Fig 2c,
e–h. By contrast, the myeloma cells stained negative for
CRBN is shown in Fig 2d. On the basis of a univariate cut-
point analysis of all possible scores and treatment response in
patients who had received LD and TD therapy, an average
IHC total score≥4.5 was used to define CRBN positivity
(CRBN+), since which generated the most balanced positive
and negative predictive value (PV+ and PV−, respectively) for
the treatment response in the LD and TD cohorts (Table 2).
There was a strong and positive correlation between the
average diffuseness score and intensity score (Pearson’s cor-
relation in reviewer A and B was 0.810 and 0.904, respective-
ly; both P<0.001). There was a good correlation for the
average total score between the reviewers (coefficient of
Pearson’s correlation, 0.891; P<0.001). The inter-reviewer
agreement on the CRBN+ showed a moderate to high corre-
lation with Cohen’s kappa value of 0.702 (P<0.001) and
Spearman’s correlation coefficient of 0.706 (P<0.001). In
the LD cohort, the myeloma cells of 19 (48 %) of the 40
patients were CRBN+. Compared to the CRBN+ RRMM
patients, CRBN-negative (CRBN−) RRMM patients had sig-
nificantly higher WBC (P=0.022). Among the 67 NDMM
patients, the myeloma cells of 39 (58 %) patients were
CRBN+. Compared to the CRBN+ NDMM patients, CRBN−
NDMM patients had significantly more ISS III (26 vs. 61 %,
respectively; P=0.006), higher level of calcium (2.2 vs.
2.4 μmol/L, respectively; P=0.045), and lower platelet counts
(2.0×1011/L vs. 1.5×1011/L, respectively; P=0.037). A signif-
icantly negative correlation was observed between CRBN
IHC status (positive vs. negative) and β2M (r=−0.283;
P=0.022) in NDMM patients.
Expression of CRBN was associated with better treatment
response in IMiDs-based treatment (not MVP treatment)
The median treatment cycle for LDwas 11 cycles (range of 1–
33 cycles). The median treatment duration for the TD and
MVP cohorts was 7 months (range of 1–38 months) and
10 months (range of 1–13 months), respectively. In the LD
and TD cohorts, CRBN+ patients had a significantly superior
treatment response (overall response rate, terms of partial
Table 1 Salient characteristics of the RRMM patients who had LD
treatment and the NDMMpatients who had TD orMVP as their induction
treatment
Disease RRMM NDMM
Treatment LD TD MVP
Pt number (n=40) (n=45) (n=22)
Sex (M/F) 25/15 28/17 11/11
Age (yrs)a 62.8±9.6 60.5±12.2 60.3±11.3
ISS, n (%)
I/II 28 (70) 30 (67) 9 (41)
III 12 (30) 15 (33) 13 (59)
Isotype, n (%)
IgG 27 (67) 20 (44) 15 (68)
IgA 9 (23) 15 (33) 6 (27)
IgD 0 (0) 2 (4) 0(0)
Light-chain 4 (10) 8 (19) 1 (5)
Kappa: lambda 1:1 1.3:1 1.2:1
HB (gm/dL)a 11.4±2.2 9.8±2.8 8.9±2.3
WBC (×109/L)a 5.7±2.6 6.4±2.8 5.6±3.8
PLA (×1011/L)a 1.7±1.0 1.9±0.8 1.7±0.9
Creatinine (mg/dL)a 1.1±0.9 1.9±2.1 1.6±1.1
Calcium (μmol/L)a 2.2±0.2 2.2±0.3 2.3±0.4
LDH (IU/L)a 431±310 394±153 605±1062
ALP (IU/L)a 200±137 228±214 152±72
CRP (mg/dL)a 1.9±4.8 2.0±2.7 1.6±3.4
Alb (gm/dL)a 3.8±0.5 3.6±0.9 3.5±0.8
β2M (mg/L)
a 6.7±12.2 8.6±13.7 10.9±8.7
Plasma cell in BM (%)a 48.6±32.4 56.9±29.8 67.3±28.0
Cytogenetic abnormalities, n (%) 8 (20) 8 (18) 2 (9)
EMM, n (%) 7 (18) 7 (16) 6 (27)
Alb albumin, ALP alkaline phosphatase, BM bone marrow, CRP C-
reactive protein, EMM extramedullary myeloma, F female,HB hemoglo-
bin, ISS international staging system, LDH lactate dehydrogenase, M
male, NDMM newly diagnosed multiple myeloma, PLA platelet, Pt
patient, RRMM relapsed and/or refractory multiple myeloma,WBC white
blood cell, β2M beta2-microglobulin
aMean±SD
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response or better) to compared CRBN− patients (LD cohort 79
vs. 33 %, respectively; P=0.005) (TD cohort CRBN+ vs.
CRBN−, 75 vs. 29 %, respectively; P=0.005); however, this
did not occur in the MVP cohort (CRBN+ vs. CRBN−, 91 vs.
82 %, respectively; P=1.000). The details of the treatment
response to various regimens between CRBN+ and CRBN−
patients are shown in Table 3. In the LD and TD cohorts, the
PV+ and PV− of CRBN+ for treatment response was 79 and 67
and 75 and 71 %, respectively. From commencement of LD,
after a median follow-up of 28 months, no significant differ-
ence was observed between CRBN+ and CRBN− patients
regarding the PFS (median, 8 vs. 8 months, respectively;
P=0.7439), TTP (median, 9 vs. 10 months, respectively;
P=0.9177), DOR (median, 9.5 months vs. not reached yet,
respectively; P=0.4752), and OS (median, not reached yet vs.
27 months, respectively; P=0.2279). In the TD cohort, 31 of
the 45 NDMM patients did not undergo further HDC/AuSCT,
and among these 31 NDMM patients, no significant difference
was observed between CRBN+ and CRBN− patients regarding
the PFS (median, 15 vs. 7 months, respectively; P=0.4600),
TTP (median, 27 vs. 7 months, respectively; P=0.6179), and
DOR (median, 12 vs. 6 months, respectively; P=0.7217).
Expression of CRBN is an independent factor associated
with treatment response of IMiDs
In the LD cohort, the salient characteristics that significantly
correlated with treatment response were CRBN+, HB ≥10g/dL
and CRP<UNL. Further multivariate analysis showed that
CRBN+ (r=7.409; 95 % confidence interval (CI) 1.57–
34.933; P=0.011) and HB ≥10g/dL (r=6.236; 95 % CI
1.127–34.498; P=0.036) were independent factors correlated
with treatment response. In the TD cohort, CRBN+, ISS I/II,
non light-chain type, and Cr <2 mg/dL were associated with
the treatment response; however, only CRBN+ (r=6.034;
95 % CI 1.328–27.422; P=0.020) and ISS I/II (r=8.807;
95 % CI 1.704–45.520; P=0.009) remained independent fac-
tors after multivariate analysis (Table 4).
Discussion
To our knowledge, this is the first study to show that CRBN
protein expression assessed by IHC in myeloma cells of BM
paraffin-embedded tissues is associated with superior treat-
ment response to LD in RRMM patients and TD in NDMM
patients. Similar to CRBN gene expression studies [14, 15],
our data indicate that CRBN is a crucial factor for the anti-
MM effect of IMiDs. A recent study also showed that higher
CRBN protein expression, determined by the overall pixel
intensity of fluorescence targeting the CRBN protein within
CD138+ cells in BM samples, correlated with superior treat-
ment response to LD than lower CRBN protein expression
[28]. Similar to other studies [15, 28], such expression of
CRBN protein was not associated with treatment response in
the regimen without IMiDs (e.g., MVP), suggesting that
CRBN is a unique biomarker for predicting the response of
IMiDs in MM patients. Although a significant difference on
a b
c d
Fig 1 Positive and negative control for the CRBN immunohistochemical
staining. Positive control for CRBN IHC staining in hepatocytes (a)
(×200) and a higher magnification (×400) for the cellular details with
positive granular cytoplasmic staining (arrow head) and positive nuclear
staining (arrow) is inserted. Negative anti-idiotype (Ig) control showing
no IHC signals in the same hepatic tissues as in a by using anti-idiotype
antibody (b) (×200). Negative control for CRBN IHC staining in cardiac
tissues is shown in (c) (×400) and a nonspecific nuclear staining is noted
in some myocardial cells (arrow head). Negative anti-idiotype (Ig) con-
trol in the same cardiac tissue as in c by using anti-idiotype antibody is
shown in (d) (×400)
Ann Hematol (2014) 93:1371–1380 1375
time to event in this study was not reached because of limited
patient numbers, a trend in favor of CRBN+ NDMM patients
compared to CRBN− NDMM patients was noted regarding
longer PFS, TTP, and DOR. These findings suggest that
identifying CRBN protein expression by the IHC may be a
clinically feasible approach for predicting treatment response
and outcome of IMiDs in MM patients.
Unlike the qRT-PCR and gene expression profiling (GEP),
which results in dose-dependent association between the
CRBN gene expression level and treatment response [14,
15], IHC staining produces, in general, non-quantified results
and is reviewer-dependent. In this study, by using the IHC
scores consisted of both diffuseness and intensity of CRBN
expression within myeloma cells, the semi-quantified results
could be obtained. This immunostain score was adopted from
the scoring system verified ever in breast cancer [25], and
such scoring systems have been introduced in order to over-
come variations, particularly for markers that are used for
making therapeutic selections [29]. Unlike the homogenous
pattern of cancer cells in solid tumors, myeloma cells within
BM always aggregated separately [1]. Therefore, we initially
picked up three hot areas of mostly aggregated myeloma cells
and evaluated the diffuseness and intensity scores of CRBN
within these sampled hot areas. Cutoff levels for assessing
whether a tissue is “positive” or “negative” can vary for the
same antigen. The optimal cutoff level, herein, was chosen by
the best balanced PV+ and PV− for the treatment response of
LD and TD. Notably, the optimal cutoff level chosen in the
LD (RRMM) cohort was nearly the same as that seen in the





Fig 2 The immunohistochemical
staining of CRBN in myeloma
cells. Aggregated myeloma cells
highlighted by CD138
membranous staining in (a) and
(b) (×400). Positive CRBN
cytoplasmic/nuclear staining in
myeloma cells with the same slice
as in a is shown in (c) (×400).
Negative CRBN staining in
myeloma cells with the same slice




cells (e) (×400) and a higher
magnification (×1000, oil lens)
for the cellular details of granular
cytoplasmic pattern is inserted.
Aggregates of myeloma cells with
intense cytoplasmic staining for
CRBN and less distinct nuclei (f)
(×1000, oil lens). Typical
myeloma cells stained positive for
CRBN (arrow) were shown in (g)
and (h) (×1000, oil lens). Several
CRBN negative myeloid and
mononuclear cells were noted in g
(arrow head) and a cluster of
CRBN negative erythrocytes are
noted in h (arrow head)
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and the cutoff level was generally reproducible. Automated
image analysis might be one of the alternative ways to mini-
mize the subjective bias on IHC interpretations between dif-
ferent reviewers, however, which is time- and cost-consuming
and is still predominantly a research tool [29]. Another prob-
lem for the automated image analysis systems is that such
analysis assesses the amount of staining by measuring absorp-
tion, so the non-linear relationship that occurs at higher and/or
lower levels between amount of antigen and intensity can
result in inaccurate readings [29]. By using the immunostain
score for CRBN and an optimal cutoff level of average total
score ≥4.5 for determining CRBN+ in the well-trained re-
viewers, there was a Cohen’s kappa score of 0.702 for the
inter-reviewer agreement, suggesting a fair to good agreement
beyond chance [26]. Unfortunately, no data on the predictivity
relating CRBN gene expression and treatment response of
IMiDs with published qRT-PCR methods could be compared
with ours. Nonetheless, IHC method may offer additional
advantages over molecular methods (e.g., GEP), such as no
requirement for cell purification by sorting, can be still used in
patients with quite low percentage of myeloma cells in BM,
lower expense and routinely available in most of the labora-
tories, ease of use, and faster turnaround time, and is still able
to offer a cost-effectiveness predictive value for the response
in several cancer treatments [25, 29]; so, it might be an
alternative method, other than qRT-PCR or GEP, to be applied
in the future study designed for biomarker enriched cohort.
Moreover, morphology is preserved in the IHC procedure,
allowing for recognition of immunostain heterogeneity and
confirmation that the identified positivity is localized to which
subcellular compartments. In CRBN+ myeloma cells, there
were mostly both positive cytoplasmic and nuclear staining
(like that seen in Figs 2c, f), but some were only positive
cytoplasmic staining (Fig 2e). It was reported that the subcel-
lular localization of CRBN was primarily in the juxtanuclear
area and cytoplasm, but inconsistently in nucleus [4, 24, 30].
The clinical significance of the different subcellular localiza-
tion of CRBN is not clear yet.
In this study, several clinical salient features were correlat-
edwith CRBN protein expression status. In general, compared
to CRBN+ patients, CRBN− patients had a more advanced
disease status, such as more prevalent ISS III. Prior studies
have indicated that MM patients with lower CRBN gene
expression had more ISS III [5, 15], which is consistent with
our results. In addition, higher levels of CRBN expression
indicate a low risk of disease [14]. A correlation was observed
between CRBN expression and chromosomal hyperdiploidy,
especially Trisomy 3 [14, 16], which is a prognostic factor
toward improved survival rates in MM patients [1, 27]. How-
ever, after adjustment of other clinical prognostic factors using
multivariate analysis, the CRBN+ in this study remained an
independent factor associated with the treatment response of
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The treatment response to LD in RRMM and TD in
NDMM patients was similar to those in other studies [31].
However, 21 % RRMM and 25 % NDMM patients did not
respond to the LD and TD regimen, respectively, despite
expression of CRBN protein within the myeloma cells, sug-
gesting the possibility of mechanisms of resistance that do not
involve CRBN. A prior study demonstrated that inducible
activation of the Wnt/β-catenin pathway by lenalidomide
treatment mediated lenalidomide resistance in MM [32],
which affects downstream targets, such as CCND1 and
MYC. Alternatively, in addition to CRBN, approximately 30
proteins were identified as potential substrate receptors [called
DDB1-CUL4-associated factors (DCAFs)] contributing to
ubiquitination of cellular proteins [7]. Competition occurs
between CRBN and other DCAFs for binding to DDB1 [4].
Therefore, when IMiDs bind to CRBN, various DCAFs may
bind to DDB1 and exhibit differing cellular functions, includ-
ing resistance. Further studies to prove this hypothesis are
required. Recently, a novel truncating mutation and R283K
point mutation of CRBN were observed in an extramedullary
plasmacytoma from a MM patient with clinical resistance to
lenalidomide, which is, however, a rare event (4 %) in MM
patients [33]. Acquired deletion of the CRBN gene was ob-
served in an in vitro study [5], as well as CRBN gene copy
reduction [9]. However, further examination of CRBN status
on additional human myeloma cell lines (HMCLs) and MM
patients suggested that copy number abnormalities affecting
the CRBN gene were rare events in MM [5]. In addition,
alternating splicing transcripts andmodification of translation-
al proteins of CRBN must be further examined. Exon 10 of
CRBN,which contains a portion of the IMiD-binding domain,
is not present in one (CRBN-002) of the isoforms of CRBN
Table 4 Univariate andmultivariate analyses among salient features and CRBN status between patients who had response to the TD induction treatment
and those who did not
With response (n=26) Without response (n=19) P value Univariate analysis Multivariate analysis
Item n (%) Odds ratio (95% CI)
CRBN+ 21 (81) 7 (37) 0.005 7.200 (1.868–27.749)a 6.034 (1.328–27.422)a
ISS I/II 23 (88) 8 (42) 0.001 10.542 (2.331–47.669)a 8.807 (1.704–45.520)a
Non light-chain type 25 (96) 12 (63) 0.006 14.583 (1.607–132.334)a –
Cytogenetic abnormalities 5 (19) 3 (16) 1.000
PC in BM >=30% 17 (65) 12 (63) 1.000
HB ≥10g/dL 16 (62) 6 (32) 0.071
PLA ≥1.5×10^11/uL 21 (59) 11 (33) 0.111
ALB ≥3.5g/dL 14 (54) 12 (63) 0.541
Cr <2.0mg/dL 25 (96) 12 (63) 0.013 12.500 (1.349–115.795)a –
ALB albumin, BM bone marrow, CI confidence interval, Cr creatinine, HB hemoglobin, ISS international staging system, PC plasma cell,
PLA platelet, WBC white blood cell
a Statistical significance
Table 3 The treatment response (according to IMWG consensus criteria) of MM patients to various regimens according to CRBN IHC staining status
Treatment LD TD MVP
CRBN status (n) Positive (19) Negative (21) P value Positive (28) Negative (17) P value Positive (11) Negative (11) P value
n (%) n (%) n (%)
CRa 0 (0) 1 (5) 0.032 2 (7) 0 (0) 0.022 3 (27) 1 (9) 0.550
VGPR 4(21) 1 (5) 7 (25) 0 (0) 2 (18) 4 (36)
PR 11 (58) 5 (23) 12 (43) 5 (29) 5 (46) 4 (36)
SD 3 (16) 10 (48) 6 (21) 9 (53) 1 (9) 2 (18)
PD 1 (5) 4 (19) 1 (4) 3 (18) 0 (0) 0 (0)
ORR (≥PR) 15 (79) 7 (33) 0.005 21 (75) 5 (29) 0.005 10 (91) 9 (81) 1.000
aDenote immunonegative complete response
CR complete response, VGPR very good partial response, PR partial response, SD stable disease, PD progressive disease, ORR overall response rate
1378 Ann Hematol (2014) 93:1371–1380
reported. The functional consequence of CRBN-002 is un-
clear; however, it may be a marker of drug resistance [17].
CBRN can be a biomarker for IMiDs sensitivity; however, it
is unclear whether it can be targeted through pharmacological
means to induce chemosensitization and reverse resistance.
The molecular mechanism to regulate the expression of CRBN
is unclear. A single NF-E2-related factor 2 (Nrf2)/antioxidant
response element (ARE) (Nrf2/ARE) site in the upstream
promoter region of mouse CRBN is responsible for most
hypoxia/reoxygenation (H/R)-dependent increases in CRBN
expression [34]. In addition, the overexpression of Nrf2 or
treatment with an Nrf2 pathway-activating chemical com-
pound (e.g., tert-butylhydroquinone) can induce the expression
of the endogenous CRBN gene [34]. These results suggest that
CRBN gene expression can be controlled by reactive oxygen
species (ROS)-dependent signaling. Therefore, it is interesting
to determine whether the expression of CRBN in myeloma
cells is also regulated by ROS signaling, and whether the
activation of the Nrf2 pathway can upregulate CRBN expres-
sion in CRBN− myeloma cells to recapture the sensitivity of
IMiDs.
This study has other limitations. First, because of the ret-
rospective nature of this study, the treatment dosage and
length varied among individual patients, which resulted in
bias in the response and outcome assessment. Further pro-
spective study with uniformly IMiDs-based treatment proto-
col and more patients enrolled is required. Second, up to date,
all the seven commercialized anti-CRBN antibodies, includ-
ing the one used in this study, are all polyclonal. The IHC
staining of CRBNmay be enhanced by the further optimizing
IHC protocol and also by the novel in-house developed mono-
clonal anti-CRBN antibody [17]. Finally, no risk-associated
fluorescent in situ hybridization (FISH) data were available in
this study; notably, the updated reports on the correlation
between CRBN expression and FISH-defined high-risk or
standard-risk MM showed controversial results [14, 35].
Conclusion
Positive CRBN protein expression assessed using IHC was
associated with superior treatment outcomes in MM patients
who received LD or TD regimens; our data indicate that
CRBN protein can be a biomarker to predict the treatment
response of IMiDs.
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